Background: The oncologic importance of threatened mesorectal fascia detected with magnetic resonance imaging is obscured by the heterogeneity of preoperative treatments. We evaluated the oncologic relevance of threatened mesorectal fascia detected with consecutive magnetic resonance imaging performed before and after long-course, concurrent chemoradiotherapy (LCRT) for mid or low rectal cancer.
Methods: We evaluated 196 patients who underwent total mesorectal excision with LCRT. Threatened mesorectal fascia was defined as a shortest distance from tumor to mesorectal fascia of ≤ 1 mm on magnetic resonance imaging. Multivariate analyses for disease-free survival using magnetic resonance imaging-based parameters were conducted with a Cox proportional hazard model before and after LCRT, respectively.
Results: The pathologic positivity of the circumferential resection margin was greater for threatened mesorectal fascia than for clear mesorectal fascia (pre-LCRT, 14.8% vs 3.0%, P = .004; post-LCRT, 15.4% vs 4.5%, P = .025). At a median follow-up of 68 months, 3-year disease-free survival was worse for threatened mesorectal fascia than for clear mesorectal fascia (pre-LCRT, 77.0% vs 88.1%, P = .023; post-LCRT, 76.9% vs 86.6%, P = .029). On multivariate analyses, threatened mesorectal fascia on pre-LCRT magnetic resonance imaging was an independent factor for poor disease-free survival (hazard ratio = 2.153, 95% confidence interval, 1.07-4.32, P = .031), whereas threatened mesorectal fascia on post-LCRT magnetic resonance imaging was not (hazard ratio = 1.689, 95% confidence interval, 0.77-3.66, P = .189).
Conclusion: This study confirms that magnetic resonance imaging-detected threatened mesorectal fascia predicts poor oncologic outcomes for mid or low rectal cancer and shows that the diagnostic performance of pre-LCRT magnetic resonance imaging is different from that of post-LCRT magnetic resonance imaging.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.surg.2017.01.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Urinary and sexual dysfunction after rectal cancer surgery: A surgical challenge.
World J Gastroenterol
December 2024
Department of Surgery and Centre of Minimal Invasive Surgery, GFO Kliniken Bonn, Bonn 53225, North Rhine-Westphalia, Germany.
This manuscript focused on the surgical challenge of urinary and sexual dysfunction after rectal cancer surgery based on the interesting results demonstrated by the observational study of Chen , which was published in the . Urinary dysfunction occurs in one-third of patients treated for rectal cancer. Surgical nerve damage is the main cause of urinary dysfunction.
View Article and Find Full Text PDFContact X-ray Brachytherapy as a Boost Therapy After Neoadjuvant (Chemo)Radiation in High-Risk Locally Advanced Rectal Cancer.
Int J Radiat Oncol Biol Phys
December 2024
Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, The University of Liverpool; Papillon Suite, The Clatterbridge Cancer Centre National Health Service Foundation Trust, Bebington, Wirral, United Kingdom. Electronic address:
Purpose: Radical surgery following neoadjuvant therapy is the standard of care for locally advanced rectal cancer. A contact x-ray brachytherapy (CXB) boost can alternatively be used to treat residual disease postneoadjuvant (chemo)radiation, especially in patients who are not suitable for or do not wish to have surgery. Its role has mostly been studied to date in low- to intermediate-risk patients.
View Article and Find Full Text PDFSystematic review of the feasibility of sparing the rectoprostatic fascia in male patients undergoing total mesorectal excision for rectal cancer.
Tech Coloproctol
December 2024
Laboratory of Anatomy, Medical School of Heraklion, University of Crete, 711 10, Voutes Heraklion, Crete, Greece.
Background: The main purpose of this study was to determine the feasibility of sparing the rectoprostatic fascia (RPF) in adult male cadavers and in adult male patients who underwent total mesorectal excision (TME) for rectal cancer. A secondary objective was to evaluate urogenital function following rectal cancer surgery, pathologic, and oncologic outcomes.
Methods: In accordance with PRISMA guidelines, we performed a systematic review with an a priori design to identify relevant studies via MESH terms and keywords.
Rectal Cancer and Lateral Lymph Node Staging: Interobserver Agreement and Success in Predicting Locoregional Recurrence.
Diagnostics (Basel)
November 2024
Department of Radiology, Adana City Training and Research Hospital, University of Health Sciences, Adana 01230, Turkey.
Article Synopsis
- The study assessed how well three radiologists agreed on MRI evaluations for staging and restaging rectal cancer in 239 patients, particularly after neoadjuvant therapy.
- The findings showed moderate to high interobserver agreement on various MRI parameters, with specific focus on tumor distance from the mesorectal fascia and lymph node involvement being significant predictors of locoregional recurrence.
- Ultimately, the analysis highlighted the importance of lymph node restaging and its correlation with locoregional recurrence rates, indicating that changes in lymph node status can influence patient outcomes.
Total neoadjuvant treatment using short-course radiotherapy and four CAPOX cycles in locally advanced rectal cancer with high-risk criteria for recurrence: a Swedish nationwide cohort study (LARCT-US).
EClinicalMedicine
September 2024
Department of Pelvic Cancer, Division Coloproctology, Karolinska University Hospital, Stockholm, Sweden.
Background: Total neoadjuvant treatment (TNT) for locally advanced rectal cancer (LARC) increases pathologic complete response (pCR) rate and reduces the risk of systemic recurrences over chemoradiotherapy (CRT) in randomised trials, e.g., the RAPIDO trial.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!